Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment: 2024

Historic Asset Writedowns and Impairment for Phathom Pharmaceuticals (PHAT) over the last 1 years, with Dec 2024 value amounting to $836,000.

  • Phathom Pharmaceuticals' Asset Writedowns and Impairment fell 132.92% to -$80,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $836,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Asset Writedowns and Impairment of $836,000 as of FY2024.
  • In the past 5 years, Phathom Pharmaceuticals' Asset Writedowns and Impairment registered a high of $836,000 during FY2024, and its lowest value of $836,000 during FY2024.
  • Over the past 1 years, Phathom Pharmaceuticals' median Asset Writedowns and Impairment value was $836,000 (recorded in 2024), while the average stood at $836,000.